1-3 of 3
Keywords: Empagliflozin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Cardiac-derived CTRP9 mediates the protection of empagliflozin against diabetes-induced male subfertility in mice

Yang Mu, Ling-Bo Luo, Rong Huang, Zhuo-Yu Shen, Dan Huang, Shu-Hong Zhao, Jing Yang, Zhen-Guo Ma
Journal: Clinical Science
Clin Sci (Lond) (2024) 138 (21): 1421–1440.
https://doi.org/10.1042/CS20241477
Published: 04 November 2024
...Yang Mu; Ling-Bo Luo; Rong Huang; Zhuo-Yu Shen; Dan Huang; Shu-Hong Zhao; Jing Yang; Zhen-Guo Ma Previous studies have shown beneficial effects of empagliflozin (Empa), a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), on diabetes and cardiovascular outcomes in patients...
View articletitled, Cardiac-derived CTRP9 mediates the protection of empagliflozin against diabetes-induced male subfertility in mice
Open the PDF for Cardiac-derived CTRP9 mediates the protection of empagliflozin against diabetes-induced male subfertility in mice in another window
Includes: Supplementary data
Articles

The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy

Ander Vergara, Carmen Llorens-Cebrià, Nerea Martos, Irene Martínez-Díaz, Frank Stein, Pamela Domínguez-Báez, Mireia Molina-Van den Bosch, Mandy Rettel, Begoña Benito, Sheila Bermejo, Michael Paul Pieper, Conxita Jacobs-Cachá, Maria José Soler
Journal: Clinical Science
Clin Sci (Lond) (2023) 137 (1): 87–104.
https://doi.org/10.1042/CS20220447
Published: 05 January 2023
... proven to delay diabetic kidney disease (DKD) progression on top of the standard of care with the renin–angiotensin system (RAS) blockade. The molecular mechanisms underlying the synergistic effect of SGLT2i and RAS blockers is poorly understood. We gave a SGLT2i (empagliflozin), an angiotensin...
View articletitled, The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy
Open the PDF for The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy in another window
Includes: Supplementary data
Articles

Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice

Mei Xue, Ting Li, Yue Wang, Yunpeng Chang, Ying Cheng, Yunhong Lu, Xiangyang Liu, Linxin Xu, Xiaoyu Li, Xiaochen Yu, Bei Sun, Liming Chen
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (15): 1705–1720.
https://doi.org/10.1042/CS20190585
Published: 02 August 2019
... as an important cause of heart failure. EMPA-REG OUTCOME trial has reported that empagliflozin, the sodium-glucose cotransporter 2 inhibitor, exerts cardiovascular benefits on diabetic population. However, the mechanism by which empagliflozin alleviates DCM still remains unclear. In the current study, we...
View articletitled, Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice
Open the PDF for Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice in another window
Includes: Supplementary data